GSK paid $1.5m to obtain an exclusive, worldwide license to products containing or directed to an undisclosed muscle disease target discovered by Five Prime using its proprietary library
The first of these agreements is a joint development program with St. Jude Children’s Research Hospital (Memphis, Tennessee, United States, "St. Jude") and the non-profit public-private partnership Medicines
The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer (CRPC) who have rising Prostate-Specific Antigen (PSA) levels and no detectable metastases. The trial is designed
Results from the study, presented during the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), also confirmed the safety profile of the combination
In October 2014, Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma
Tecemotide was being assessed in the Phase III START2, START and INSPIRE trials to treat unresectable, locally advanced Stage III NSCLC. In 2007, the company received the exclusive
The new joint venture (JV) will be known as TIPR-HUYA Advancing Innovative Medicines (TIPR-HUYA-AIM). Under the deal, the two firms will share equally in decision-making regarding product development
Preeclampsia is one of the most common complications of pregnancy and it leads to increased risk of maternal mortality, perinatal fetal mortality, fetal pre-maturity, or even the need
SYN-005 is being developed through Synthetic Biologics’ exclusive channel collaboration with Intrexon (XON) and academic researchers at the University of Texas at Austin to target and neutralize the
Made from allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cells (hUCB-MSCs), PNEUMOSTEM is expected to have effect on regenerating the lung tissue and improving inflammatory responses in premature
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.